AI Terminal
DIACEUTICS PLC
Regulatory Filings • Mar 22, 2022
7596_rns_2022-03-22_78370425-1012-4b55-b1c5-6a9cc38345c0.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 5261F
Diaceutics PLC
22 March 2022
22 March 2022
Diaceutics PLC
Notice of 2021 Full Year Results
Diaceutics PLC (the "Company" or the "Group"), the diagnostic commercialisation company for precision testing, announces that due to a short delay in the completion of the audit of its results for the year-ended 31 December 2021, these are expected to be released later today.
No changes are expected to the results outlined in the trading update announced on the 11 January 2022.
Enquiries:
| Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer | Via Alma PR |
| Nick Roberts, Chief Financial Officer | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Stewart Wallace | |
| Nick Adams | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | [email protected] |
| Kieran Breheny | |
| Matthew Young |
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORDXGDXGGDDGDB